Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
The array of genome editing strategies based on targeted double-stranded DNA break formation have recently been enriched through the introduction of transcription activator-like type III effector (TALE) nucleases (TALENs). To advance the testing of TALE-based approaches, it will be crucial to deliver these custom-designed proteins not only into transformed cell types but also into more relevant, chromosomally stable, primary cells. Viral vectors are among the most effective gene transfer vehicles. Here, we investigated the capacity of human immunodeficiency virus type 1- and adenovirus-based vectors to package and deliver functional TALEN genes into various human cell types. To this end, we attempted to assemble particles of these two vector classes, each encoding a monomer of a TALEN pair targeted to a bipartite sequence within the AAVS1 'safe harbor' locus. Vector DNA analyses revealed that adenoviral vectors transferred intact TALEN genes, whereas lentiviral vectors failed to do so, as shown by their heterogeneously sized proviruses in target cells. Importantly, adenoviral vector-mediated TALEN gene delivery resulted in site-specific double-stranded DNA break formation at the intended AAVS1 target site at similarly high levels in both transformed and non-transformed cells. In conclusion, we demonstrate that adenoviral, but not lentiviral, vectors constitute a valuable TALEN gene delivery platform.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, the CRISPR system has the potential to be delivered by lentivirus vectors, whereas TALENs do not because of their large size and repeat sequences 23 .”
From Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus (2013) · cites this paper as [23]
Experimental — accuracy not yet measuredIn the citing paper
“However, although attempts to express TALEN in lentiviral vectors have failed, it has been expressed successfully in adenoviral vectors [82].”
From Newer Gene Editing Technologies toward HIV Gene Therapy (2013) · cites this paper as [82]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors
Boch, J., Scholze, H., Schornack, S., Landgraf, A., Hahn, S., Kay, S., Lahaye, T., Nickstadt, A., & Bonas, U. (2009) · Science · doi:10.1126/science.1178811 · Cited by 2,470 · cited 2×
“Crucially, it has been discovered that each individual RVD dictates the binding of the repeat in which it is embedded to a single nucleotide (5,6).”
BackgroundA TALE nuclease architecture for efficient genome editing
Miller, J. C., Tan, S., Qiao, G., Barlow, K. A., Wang, J., Xia, D. F., Meng, X., Paschon, D. E., Leung, E., Hinkley, S. J., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1755 · Cited by 2,098 · cited 1×
“Hitherto, designer TALEs tested in vitro and in cellula have included those with transcriptional activation or FokI nuclease domains (8,9).”
BackgroundA Simple Cipher Governs DNA Recognition by TAL Effectors
Moscou, M. J., & Bogdanove, A. J. (2009) · Science · doi:10.1126/science.1178817 · Cited by 1,988 · cited 2×
“Crucially, it has been discovered that each individual RVD dictates the binding of the repeat in which it is embedded to a single nucleotide (5,6).”
BackgroundHybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain.
Kim, Y. G., Cha, J., & Chandrasegaran, S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.3.1156 · Cited by 1,889 · cited 4×
“Hitherto, designer TALEs tested in vitro and in cellula have included those with transcriptional activation or FokI nuclease domains (8,9).”
BackgroundInfluentialGenetic engineering of human pluripotent cells using TALE nucleases
Hockemeyer, D., Wang, H., Kiani, S., Lai, C. S., Gao, Q., Cassady, J. P., Cost, G. J., Zhang, L., Santiago, Y., Miller, J. C., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1927 · Cited by 1,135
Xanthomonas AvrBs3 Family-Type III Effectors: Discovery and Function
Boch, J., & Bonas, U. (2010) · Annual Review of Phytopathology · doi:10.1146/annurev-phyto-080508-081936 · Cited by 978 · cited 1×
“5 repeat units with circa 34 residues each (7).”
BackgroundRepeat instability: mechanisms of dynamic mutations
Pearson, C. E., Edamura, K. N., & Cleary, J. D. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1689 · Cited by 924 · cited 1×
“Indeed, examples of both physiological and functionimpairing processes associated with instability of tandem repeats are copious and cover virtually all biological systems from viruses and prokaryotes to eukaryotes (44-46).”
BackgroundLombardo, A., Genovese, P., Beausejour, C. M., Colleoni, S., Lee, Y.-L., Kim, K. A., Ando, D., Urnov, F. D., Galli, C., Gregory, P. D., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1353 · Cited by 845 · cited 1×
“of transposases, homing endonucleases and zinc finger nucleases (33-36).”
BackgroundA novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity
Mussolino, C., Morbitzer, R., Lütge, F., Dannemann, N., Lahaye, T., & Cathomen, T. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr597 · Cited by 714 · cited 2×
“A TALEN pair (Supplementary Figure S1) targeting intron 1 of the PPP1R12C locus (AAVS1 target site: 50-TCTGTCCCCTCCACCCCAC-spacer-GACAGGAT TGGTGACAGAA-30) were generated by Golden Gate cloning, as previously described (9).”
BackgroundMethodSelf-citationRepeat instability : mechanisms of dynamic mutations
Pearson, C. E. (2005) · Medical Entomology and Zoology · Cited by 711
Research works printed but not linked: 1
- Coffin JM Hughes SH Varmus HE Retroviruses 1997 NY Cold Spring Harbor Laboratory Press, Cold Spring Harbor 21433340
Cited by
Items 101–200 of 312
Genetic correction using engineered nucleases for gene therapy applications
Lisa Li, H., Nakano, T., & Hotta, A. (2014) · Development, Growth & Differentiation · doi:10.1111/dgd.12107 · Cited by 48
A platform for rapid generation of single and multiplexed reporters in human iPSC lines
Pei, Y., Sierra, G., Sivapatham, R., Swistowski, A., Rao, M. S., & Zeng, X. (2015) · Scientific Reports · doi:10.1038/srep09205 · Cited by 48
Strauβ, A., & Lahaye, T. (2013) · Molecular Plant · doi:10.1093/mp/sst075 · Cited by 47
“Indeed, recent studies revealed that genes encoding TALENs are instable in lentiviral vectors (Holkers et al., 2013), which likely is due to the repetitive nature and size of genes encoding TALE repeat arrays.”
BackgroundEngineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression
Kabadi, A. M., & Gersbach, C. A. (2014) · Methods · doi:10.1016/j.ymeth.2014.06.014 · Cited by 46
Genome editing strategies: potential tools for eradicating HIV-1/AIDS
Khalili, K., Kaminski, R., Gordon, J., Cosentino, L., & Hu, W. (2015) · Journal of NeuroVirology · doi:10.1007/s13365-014-0308-9 · Cited by 56
“Therefore, the ability to construct functional TALEN pairs with large numbers of repeats may increase their potential specificity when compared to ZFNs (Holkers et al. 2013).”
BackgroundProgrammable Molecular Scissors: Applications of a New Tool for Genome Editing in Biotech
Saha, S. K., Saikot, F. K., Rahman, M. S., Jamal, M. A. H. M., Rahman, S. M. K., Islam, S. M. R., & Kim, K. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.11.016 · Cited by 51
“Cloning DNA segments that encode TALE arrays involves certain technical challenges posed by large similar repeat sequences, requirement of approximately 20 RVDs, and increased consumption of cost.(61) Numerous techniques for rapid assembly of custom TALE arrays include: Golden Gate cloning systems,(62) solid-phase ass…”
MethodSong, M. (2017) · Biotechnology Progress · doi:10.1002/btpr.2484 · Cited by 43
“IDLVs often cause unwanted rearrangements of repetitive sequences such as TALENs, leading to undesired gene modifications.(40) However, according to the recent study by Cai et al.”
ResultBurrH: a new modular DNA binding protein for genome engineering
Juillerat, A., Bertonati, C., Dubois, G., Guyot, V., Thomas, S., Valton, J., Beurdeley, M., Silva, G. H., Daboussi, F., & Duchateau, P. N. (2014) · Scientific Reports · doi:10.1038/srep03831 · Cited by 46
Present and Future Therapies for Chronic Hepatitis B
Tao, Y.-C., Wu, D., Zhou, L., Chen, E., Liu, C., Tang, X., Jiang, W., Han, N., Li, H., & Tang, H. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-9151-4_6 · Cited by 45
Targeting Human MicroRNA Genes Using Engineered Tal-Effector Nucleases (TALENs)
Hu, R., Wallace, J., Dahlem, T. J., Grunwald, D. J., & O'Connell, R. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063074 · Cited by 41
“However, the development of viral vector systems that enable transient expression of TALENs in specific cell types is necessary for many important applications in vivo [15].”
BackgroundGenomic Analysis of Sleeping Beauty Transposon Integration in Human Somatic Cells
Turchiano, G., Latella, M. C., Gogol‐Döring, A., Cattoglio, C., Mavilio, F., Izsvák, Z., Ivics, Z., & Recchia, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112712 · Cited by 46
“step resulting in partially-deleted integrated proviruses, a frequent occurrence in transgene hosting repetitive sequences [44,45].”
BackgroundSelf-citationNovel Genome-Editing Tools to Model and Correct Primary Immunodeficiencies
de Bruin, L. M. O., Volpi, S., & Musunuru, K. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00250 · Cited by 46
“Moreover, the highly repetitive nature of TALEN sequences due to their tandem arrays makes them more challenging to package into viral vectors for delivery (56).”
Drug addiction and treatment: An epigenetic perspective
Koijam, A. S., Singh, K. D., Singh, N. B., Haobam, R., & Rajashekar, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115951 · Cited by 53
The Development of TALE Nucleases for Biotechnology
Ousterout, D. G., & Gersbach, C. A. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2932-0_3 · Cited by 44
“Adenovirus presents an attractive delivery vehicle for delivering gene constructs encoding both TALEN monomers (84), although adenovirus has limited tropism in some cell types and is highly immunogenic.”
BackgroundCRISPR-Cas9: from Genome Editing to Cancer Research
Chen, S., Sun, H., Miao, K., & Deng, C. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.17421 · Cited by 47
“Another technique barrier is low screening efficiency for successful targeted cells [20].”
BackgroundCRISPR/Cas9 Technology: Applications and Human Disease Modeling
Martínez-Lage, M., Torres-Ruiz, R., & Rodríguez, S. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.09.002 · Cited by 47
Beyond the Antigen Receptor: Editing the Genome of T-Cells for Cancer Adoptive Cellular Therapies
Lloyd, A., Vickery, O. N., & Laugel, B. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00221 · Cited by 36
“Of note it was recently shown that, due to their very repetitive nature, TAL arrays were incompatible with efficient reverse transcription required for the delivery of genetic material using lentiviruses (36), thereby limiting the range of delivery methods for TALENs.”
BackgroundHBV cccDNA and Its Potential as a Therapeutic Target
Zhu, A., Liao, X., Li, S., Zhao, H., Chen, L., Xu, M., & Duan, X. (2019) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2018.00054 · Cited by 39
“[47] Holkers M, Maggio I, Liu J, Janssen JM, Miselli F, Mussolino C, et al.”
BackgroundVives-Vallés, J. A., & Collonnier, C. (2020) · Frontiers in Plant Science · doi:10.3389/fpls.2019.01813 · Cited by 43
Zhang, W., Solanki, M., Müther, N., Ebel, M., Wang, J., Sun, C., Izsvák, Z., & Ehrhardt, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076771 · Cited by 38
“These genetic elements included bacteriophage derived integrase PhiC31 for somatic integration into genomic hot spots [33], zinc finger nucleases (ZFNs) and transcription activator like elements (TALEN) [34-36] for gene insertion at pre-determined genomic loci, retrotransposons from somatic integration [37], AAV Rep p…”
MethodMerkert, S., Wunderlich, S., Bednarski, C., Beier, J., Haase, A., Dreyer, A.-K., Schwanke, K., Meyer, J., Göhring, G., Cathomen, T., et al. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2013.12.003 · Cited by 36
“In addition to the experiments with the ZFNs, transfection experiments with AAVS1-specific TALENs were performed with one hiPSC line.”
InfluentialSelf-citationAminoacyl tRNA synthetases as malarial drug targets: a comparative bioinformatics study
Nyamai, D. W., & Bishop, Ö. T. (2019) · Malaria Journal · doi:10.1186/s12936-019-2665-6 · Cited by 41
Lentiviral Vectors in Cancer Immunotherapy
Oldham, R. A. A., Berinstein, E. M., & Medin, J. A. (2015) · Immunotherapy · doi:10.2217/imt.14.108 · Cited by 42
Construction and characterization of adenoviral vectors for the delivery of TALENs into human cells
Holkers, M., Cathomen, T., & Gonçalves, M. A. F. V. (2014) · Methods · doi:10.1016/j.ymeth.2014.02.017 · Cited by 37
Self-citationMarch, O. P., Reichelt, J., & Koller, U. (2017) · Experimental Physiology · doi:10.1113/ep086044 · Cited by 34
“Although their size prohibits viral delivery and transfection in protein form, they are also susceptible to rearrangements of the almost identical repeats in mRNA form during retroviral transduction (Holkers et al. 2013).”
BackgroundTasca, F., Wang, Q., & Gonçalves, M. A. F. V. (2020) · Cells · doi:10.3390/cells9040953 · Cited by 37
“In fact, Holkers and co-workers demonstrated that, in contrast to HIV-1-based lentiviral vectors, transgenes encoding TALENs can be transferred intact into human cells by AdVs [103].”
BackgroundMethodInfluentialSelf-citationA genome editing primer for the hematologist
Hoban, M. D., & Bauer, D. E. (2016) · Blood · doi:10.1182/blood-2016-01-678151 · Cited by 35
“TALENs have proven difficult to deliver viaAAVor lentiviral vectors due to their large size andhighly repetitive sequences.(118) Delivery of SpCas9 via AAV is particularly challenging given that the gene itself nearly outstrips the viral genome cargo limit, leaving very little room for regulatory elements, sgRNA casse…”
BackgroundApplications of Alternative Nucleases in the Age of CRISPR/Cas9
Guha, T. K., & Edgell, D. R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122565 · Cited by 43
“However, the repeated nature of the RVDs, coupled with the large coding size of TALENs (~5 kb each), posed difficulties for assembly and delivery of dimeric TALENs in size-constrained vectors, particularly in mammalian systems [29].”
BackgroundEditing CCR5: A Novel Approach to HIV Gene Therapy
Cornu, T. I., Mussolino, C., Bloom, K. M., & Cathomen, T. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-2432-5_6 · Cited by 39
Self-citationTay, F. C., Tan, W. K., Goh, S.-L., Ramachandra, C. J. A., Lau, C., Zhu, H., Chen, C., Du, S., Phang, R.-Z., Shahbazi, M., et al. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2745 · Cited by 33
“This is because the design architecture of TALENs contains repeated sequences in RVDs and viruses are often prone to genetic recombination when repeated sequences are present, making it difficult to generate effective TALEN-expressing viral vectors [37].”
BackgroundGene Therapy for Inherited Retinal Degeneration
Arbabi, A., Liu, A., & Ameri, H. (2019) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0087 · Cited by 30
“130 TALEN 131 and ZFN 132 are programmable site-specific nucleases, providing permanent and precise genome editing by inducing DSBs followed by nonhomologous end joining (NHEJ) or homology-directed repair (HDR) mechanisms.”
Gene editing and its application for hematological diseases
Osborn, M. J., Belanto, J. J., Tolar, J., & Voytas, D. F. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2017-z · Cited by 36
“Furthermore, TALENs are readily deliverable as mRNA; however, their large, repetitive nature limits their use in some DNA and viral vectors [26].”
CRISPR/Cas-Mediated Genome Editing for Sugarcane Improvement
Mall, A. K., Manimekalai, R., Misra, V., Pandey, H., Srivastava, S., & Sharma, A. (2024) · Sugar Tech · doi:10.1007/s12355-023-01352-2 · Cited by 31
“However, TALENs are easy to design due to the presence of one-to-one recognition rules between protein repeats and nucleotide sequences (Holkers et al. 2013).”
Biomaterial-Based CRISPR/Cas9 Delivery Systems for Tumor Treatment
Li, M., Chen, F., Yang, Q., Tang, Q., Xiao, Z., Tong, X., Zhang, Y., Lei, L., & Li, S. (2024) · Biomaterials Research · doi:10.34133/bmr.0023 · Cited by 36
“Alternatively, the invariance and high repetition of the TALEN consensus sequence results in inefficient overall assembly [11–13].”
The therapeutic landscape of HIV-1 via genome editing
Kwarteng, A., Ahuno, S. T., & Kwakye-Nuako, G. (2017) · AIDS Research and Therapy · doi:10.1186/s12981-017-0157-8 · Cited by 37
“Adenovirus vectors are superior in transducing targeted cells with programmable nucleases and promote high site-specific double-stranded DNA breaks [119].”
BackgroundOncolytic Adenoviruses: Strategies for Improved Targeting and Specificity
Hajeri, P. B., Sharma, N., & Yamamoto, M. (2020) · Cancers · doi:10.3390/cancers12061504 · Cited by 31
Weber, N. D., Aubert, M., Dang, C. H., Stone, D., & Jerome, K. R. (2014) · Virology · doi:10.1016/j.virol.2013.12.037 · Cited by 30
“Additionally, the existence of a high number of near-identical repeats in the coding sequence of modular enzymes (ZFNs and TALENs) may promote recombination and genome instability during production of viral vectors [53].”
BackgroundDuhamel, M., Rose, M., Rodet, F., Murgoci, A., Zografidou, L., Régnier‐Vigouroux, A., Abeele, F. V., Kobeissy, F. H., Nataf, S., Pays, L., et al. (2018) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra117.000443 · Cited by 32
Barcode-free next-generation sequencing error validation for ultra-rare variant detection
Yeom, H., Lee, Y., Ryu, T., Noh, J., Lee, A. C., Lee, H., Kang, E., Song, S. W., & Kwon, S. (2019) · Nature Communications · doi:10.1038/s41467-019-08941-4 · Cited by 31
Gene Expression Variability as a Unifying Element of the Pluripotency Network
Mason, E. A., Mar, J. C., Laslett, A. L., Pera, M. F., Quackenbush, J. F., Wolvetang, E. J., & Wells, C. A. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.06.008 · Cited by 30
Bone Marrow Gene Therapy for HIV/AIDS
Herrera-Carrillo, E., & Berkhout, B. (2015) · Viruses · doi:10.3390/v7072804 · Cited by 32
“Most studies have focused on the genes encoding the HIV-1 co-receptor CCR5 and CXCR4, but the integrated HIV-1 DNA genome can also be targeted [48–56].”
BackgroundThe emerging role of viral vectors as vehicles for DMD gene editing
Maggio, I., Chen, X., & Gonçalves, M. A. F. V. (2016) · Genome Medicine · doi:10.1186/s13073-016-0316-x · Cited by 28
Self-citationCottle, R. N., Lee, C. M., Archer, D. R., & Bao, G. (2015) · Scientific Reports · doi:10.1038/srep16031 · Cited by 32
SILVA, M. C. D. L. D., Chibucos, M. C., Munro, J. B., Daugherty, S., Coelho, M. M., & da Silva, J. C. F. (2020) · Scientific Reports · doi:10.1038/s41598-019-56950-6 · Cited by 25
Sundaresan, Y., Yacoub, S., Kodati, B., Amankwa, C. E., Raola, A., & Zode, G. S. (2023) · FEBS Journal · doi:10.1111/febs.16771 · Cited by 29
“Also, TALENs are relatively large proteins with repetitive sequences compared to ZFN, which may impair packaging, delivery and expression of the desired gene sequence [14].”
BackgroundPrime Editing: A Revolutionary Technology for Precise Treatment of Genetic Disorders
Li, M., Lin, Y., Cheng, Q., & Wei, T. (2025) · Cell Proliferation · doi:10.1111/cpr.13808 · Cited by 33
“Different serotypes of AdVs have been employed for PE in human cells [118–120].”
Emerging gene editing strategies for Duchenne muscular dystrophy targeting stem cells
Bertoni, C. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00148 · Cited by 28
“Promising results have been obtained using adenoviral vectors (Perez et al., 2008; Holkers et al., 2013) and adeno-associated virus vectors which have been shown to drive efficient expression of the nucleases into cells (Porteus et al., 2003; Gellhaus et al., 2010; Metzger et al., 2011).”
BackgroundLiu, J., & Shui, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.014 · Cited by 28
“15 as the RVD repeat region in TALEN genes [158].”
BackgroundSelf-citationGenome Editing Strategies to Protect Livestock from Viral Infections
Söllner, J.-H., Mettenleiter, T. C., & Petersen, B. (2021) · Viruses · doi:10.3390/v13101996 · Cited by 29
“TALENs and Zinc-finger nucleases are known for their limitations, such as available target sites [53], target specificity [54], and laboriousness [55]; hence, CRISPR/Cas was rapidly adapted for most genomic engineering experiments.”
BackgroundZhang, Z., Wu, E., Qian, Z., & Wu, W.-S. (2014) · Scientific Reports · doi:10.1038/srep07338 · Cited by 28
Utilization of TALEN and CRISPR/Cas9 technologies for gene targeting and modification
Pu, J., Frescas, D., Zhang, B., & Feng, J. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370215584932 · Cited by 26
Lentiviral vectors in cancer immunotherapy
Lin, S., Wang, B., & Wang, L. (2008) · 国际外科学杂志 · doi:10.3760/cma.j.issn.1673-4203.2008.03.011 · Cited by 23
DNA-binding proteins from marine bacteria expand the known sequence diversity of TALE-like repeats
de Lange, O., Wolf, C., Thiel, P., Krüger, J., Kleusch, C., Kohlbacher, O., & Lahaye, T. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1053 · Cited by 28
Towards combinatorial transcriptional engineering
Mehrotra, R., Renganaath, K., Kanodia, H., Loake, G. J., & Mehrotra, S. (2017) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.03.006 · Cited by 23
“Secondly, the repetitive nature of TALEs decreases the genomic stability of their corresponding DNA sequences due to their high recombination propensity (Holkers et al., 2013).”
Applications of CRISPR-Cas in Bioengineering, Biotechnology, and Translational Research
Lau, C. (2018) · The CRISPR Journal · doi:10.1089/crispr.2018.0026 · Cited by 24
“18 The most widely used CRISPR system consists of a single guide RNA (sgRNA) and a SpCas9 nuclease (also known as Cas9).”
BuD, a helix–loop–helix DNA-binding domain for genome modification
Stella, S., Molina, R., Mendez, B. L., Juillerat, A., Bertonati, C., Daboussi, F., Campos‐Olivas, R., Duchateau, P., & Montoya, G. (2014) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s1399004714011183 · Cited by 26
“This represents an advantage with respect to TALE, whose DNA sequences are prone to rearrangements when delivered by lentivirus in target cells owing to their highly repetitive DNA sequence (Holkers et al., 2013).”
BackgroundTranscription activator‐like effector nucleases (TALENs): An efficient tool for plant genome editing
Bhushan, K., Pratap, D., & Sharma, P. K. (2016) · Engineering in Life Sciences · doi:10.1002/elsc.201500126 · Cited by 29
“The high-repetitive TALE sequences are prone to extensive rearrangement if delivered through lentiviral vectors [32].”
BackgroundZhou, W., Yang, J., Zhang, Y., Hu, X., & Wang, W. (2022) · MedComm · doi:10.1002/mco2.155 · Cited by 32
Proven and novel strategies for efficient editing of the human genome
Mussolino, C., Mlambo, T., & Cathomen, T. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.08.008 · Cited by 23
Self-citationGenome Editing: Potential Treatment for Lysosomal Storage Diseases
de Carvalho, T. G., Matte, Ú. D. S., Giugliani, R., & Baldo, G. (2015) · Current Stem Cell Reports · doi:10.1007/s40778-014-0007-8 · Cited by 26
Pelascini, L. P. L., Maggio, I., Liu, J., Holkers, M., Cathomen, T., & Gonçalves, M. A. F. V. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.107 · Cited by 25
“The utility of these integrase-defective LVs (IDLVs) is broad since, with the exception of transcription activatorlike effector nucleases (Holkers et al., 2013), they can serve as episomal templates for the synthesis of functional genome-modifying enzymes.”
Self-citationGenome editing-based HIV therapies
Gu, W.-G. (2015) · Trends in biotechnology · doi:10.1016/j.tibtech.2014.12.006 · Cited by 24
Rapid Assembly of Customized TALENs into Multiple Delivery Systems
Zhang, Z., Zhang, S., Huang, X., Orwig, K. E., & Sheng, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080281 · Cited by 21
“During preparation of this manuscript, Holkers and co-workers reported similar success using adenoviruses to introduce TALEN sequences into HeLa cells with a different strategy [52].”
Targeted mutagenesis: A sniper-like diversity generator in microbial engineering
Zheng, X., Xing, X., & Zhang, C. (2017) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2017.07.001 · Cited by 22
“However, TALENs generally consist of almost 20 tandem repeats of TALEs [83], the conserved sequences among them are prone to rearrange through recombination, producing random truncations, which is a main cause for construction in and delivery failure [99].”
BackgroundA single-chain TALEN architecture for genome engineering
Sun, N., & Zhao, H. (2013) · Molecular BioSystems · doi:10.1039/c3mb70412b · Cited by 23
Application of genome editing technologies to the study and treatment of hematological disease
Pellagatti, A., Dolatshad, H., Yip, B. H., Valletta, S., & Boultwood, J. (2015) · Advances in Biological Regulation · doi:10.1016/j.jbior.2015.09.005 · Cited by 23
Spanevello, F., Calistri, A., Vecchio, C. D., Mantelli, B., Frasson, C., Basso, G., Palù, G., Cavazzana, M., & Parolin, C. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.24 · Cited by 28
Editing out HIV: application of gene editing technology to achieve functional cure
Xun, J., Zhang, X., Guo, S., Lu, H., & Chen, J. (2021) · Retrovirology · doi:10.1186/s12977-021-00581-1 · Cited by 24
Zhu, W., Filice, D., Palpant, N. J., & Laflamme, M. A. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1047-2_20 · Cited by 19
Lau, C., Zhu, H., Tay, J. C.-K., Li, Z., Tay, F. C., Chen, C., Tan, W.-K., Du, S., Sia, V.-K., Phang, R.-Z., et al. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.50 · Cited by 19
Viral Vectors, Engineered Cells and the CRISPR Revolution
DiCarlo, J. E., Deeconda, A., & Tsang, S. H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-63904-8_1 · Cited by 21
Genome engineering in insects: focus on the CRISPR/Cas9 system
Hillary, V. E., Ceasar, S. A., & Savarimuthu Ignacimuthu, S. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818140-9.00018-0 · Cited by 25
Genome editing technologies to fight infectious diseases
Trevisan, M., Palù, G., & Barzon, L. (2017) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1400379 · Cited by 18
“undesired recombination during the production process [164].”
Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA
Ohno, M., Otsuka, M., Kishikawa, T., Yoshikawa, T., Takata, A., & Koike, K. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i23.7084 · Cited by 20
Emerging Therapeutic Approaches for Diamond Blackfan Anemia
Aspesi, A., Borsotti, C., & Follenzi, A. (2018) · Current Gene Therapy · doi:10.2174/1566523218666181109124538 · Cited by 23
“This model developed macrocytic anemia and BM failure that were recovered in vitro and in vivo by RPS19 gene transfer using LVs [60, 61].”
BackgroundInfluentialSingh, S., & Ramakrishna, W. (2021) · 3 Biotech · doi:10.1007/s13205-021-03041-x · Cited by 23
Wang, T., Xie, Y., Tan, A., Li, S., & Xie, Z. (2015) · ACS Synthetic Biology · doi:10.1021/acssynbio.5b00180 · Cited by 17
Chimeric Antigen Receptor T Cells: Extending Translation from Liquid to Solid Tumors
Morgan, M. A., & Schambach, A. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.251 · Cited by 18
Genome Engineering in Human Cells
Song, M., Kim, Y., Kim, J., & Kim, S. (2014) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-801185-0.00005-2 · Cited by 18
Genome-editing tools for stem cell biology
Vasileva, E., Shuvalov, O. Y., Garabadgiu, A. V., Melino, G., & Barlev, N. A. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.167 · Cited by 20
“TALENs and TALE-TFs: On the basis of the TALE protein TALENs genome-editing system has been successfully applied for genome modification in plants,(18) insects,(19) nematodes,(20) the fish,(21) amphibians,(22) mice,(23) rats,(24) rabbits,(25) cancer human cell lines, hESCs and iPSCs.(26,27) The most important componen…”
MethodUse of Genome Editing Techniques to Produce Transgenic Farm Animals
Hay, A. N., Farrell, K., Leeth, C. M., & Lee, K. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-85686-1_14 · Cited by 17
Targeted biallelic integration of an inducible Caspase 9 suicide gene in iPSCs for safer therapies
Wunderlich, S., Haase, A., Merkert, S., Jahn, K., Deest, M., Frieling, H., Glage, S., Korte, W., Martens, A., Kirschning, A., et al. (2022) · Molecular Therapy: Methods & Clinical Development · doi:10.1016/j.omtm.2022.05.011 · Cited by 16
Genome-Edited T Cell Therapies
Delhove, J. M. K. M., & Qasim, W. (2017) · Current Stem Cell Reports · doi:10.1007/s40778-017-0077-5 · Cited by 19
Yu, A. Q., Ding, Y., Lu, Z. Y., Yan, H., Teng, Z., Yan, S., Li, D., & Zeng, Y. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7889 · Cited by 19
“To the best of our knowledge, homozygous deletion of a predetermined length of genomic DNA using ZFNs, TALENs or CRISPR/Cas9 has not been previously reported.”
InfluentialThe history of phytoremediation
Tonelli, F. M. P., Bhat, R. A., Dar, G. H., & Hakeem, K. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-89874-4.00018-2 · Cited by 22
Delivering the Goods for Genome Engineering and Editing
Skipper, K. A., & Mikkelsen, J. G. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.063 · Cited by 21
“70 In a similar fashion, adeno-associated vectors (AAVs) have been adapted for nuclease delivery.”
Applications of the CRISPR/Cas9 system in murine cancer modeling
Zuckermann, M., Kawauchi, D., & Gronych, J. (2016) · Briefings in Functional Genomics · doi:10.1093/bfgp/elw021 · Cited by 16
Application of CRISPR/Cas system for genome editing in cotton
Fiaz, S., Khan, S. A., Younas, A., Shahzad, K., Ali, H., Noor, M. A., Ashraf, U., & Nadeem, F. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821910-2.00010-2 · Cited by 18
Potential mechanisms for cell-based gene therapy to treat HIV/AIDS
Herrera-Carrillo, E., & Berkhout, B. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.980236 · Cited by 16
“Although several groups have used TALENs to modify endogenous genes in different species [78], there are only a few studies that have used this system for HIV-1 gene therapy applications [79-81].”
BackgroundCRISPR/Cas9; A robust technology for producing genetically engineered plants
Farooq, R., Hussain, K., Nazir, S., Javed, M. R., & Masood, N. (2018) · Cellular and Molecular Biology · doi:10.14715/cmb/2018.64.14.6 · Cited by 17
Bloom, K. M., Mussolino, C., & Arbuthnot, P. B. (2015) · Current Stem Cell Reports · doi:10.1007/s40778-014-0008-7 · Cited by 16
Self-citationMehnath, S. (2025) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgaf127 · Cited by 15
New horizon for radical cure of chronic hepatitis B virus infection
Tajiri, K., & Shimizu, Y. (2016) · World Journal of Hepatology · doi:10.4254/wjh.v8.i21.863 · Cited by 15
Design, Assembly, and Characterization of TALE-Based Transcriptional Activators and Repressors
Thakore, P. I., & Gersbach, C. A. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2932-0_7 · Cited by 18
Zhang, J., Cao, Z., Ding, X., Wei, X., Zhang, X., Hou, J., & Ouyang, J. (2017) · PubMed Central · Cited by 16
Genome editing: a robust technology for human stem cells
Chandrasekaran, A. P., Song, M., & Ramakrishna, S. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2522-0 · Cited by 14
“In contrast, TALEN sequences are stably maintained in adenoviral plasmid vectors, suggesting that adenoviral vectors may be highly effective for the delivery of full-length TALENs to human cells [42].”
BackgroundMethodWidely used gene editing strategies in cancer treatment a systematic review
Suleiman, A. A., Saedi, W. Y., & Muhaidi, M. J. (2020) · Gene Reports · doi:10.1016/j.genrep.2020.100983 · Cited by 19
Siva, N., Gupta, S., Gupta, A., Shukla, J. N., Malik, B., & Shukla, N. (2021) · 3 Biotech · doi:10.1007/s13205-021-02680-4 · Cited by 17
Recent developments in genome editing for potential use in plants
Townson, J. (2017) · Bioscience Horizons The International Journal of Student Research · doi:10.1093/biohorizons/hzx016 · Cited by 14
Targeted mutation of GA20ox-2 gene using CRISPR/Cas9 system generated semi-dwarf phenotype in rice
Santoso, T. J., Trijatmiko, K. R., Char, S. N., Yang, B., & Wang, K. (2020) · IOP Conference Series Earth and Environmental Science · doi:10.1088/1755-1315/482/1/012027 · Cited by 13
Metadata
- Authors
- Holkers, M., Maggio, I., Liu, J., Janssen, J. M., Miselli, F., Mussolino, C., Recchia, A., Cathomen, T., & Gonçalves, M. A. F. V.
- Affiliations
- University of Modena and Reggio Emilia (IT)
- Corresponding author
- Gonçalves, Manuel A. F. V.
- ORCID
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-12-26
- Volume
- 41
- Issue
- 5
- Pages
- e63-e63
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC3597656
- OpenAlex
- W2090787765
- Cited by
- 312
- References
- 62
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 14 · 2023: 9 · 2022: 10 · 2021: 17 · 2020: 17 · 2019: 16 · 2018: 23 · 2017: 33 · 2016: 42 · 2015: 47 · 2014: 44 · 2013: 21
- FWCI
- 21.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Funders
- European Commission (222878)
- Universiteit Leiden
- Prinses Beatrix Spierfonds (W.OR11–18)
- Leids Universitair Medisch Centrum
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- TALE nucleases, adenoviral vector, lentiviral vectors, HIV-1-based vectors, AAVS1 safe harbor, genome editing, DNA double-strand breaks, primary human cells
- MeSH terms
- Adenoviridae, Bacterial Proteins, Chromosomes, Human, Deoxyribonucleases, Genetic Vectors, HeLa Cells, Humans, Transduction, Genetic, HIV-1, DNA Breaks, Double-Stranded, Genetic Loci, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.